drugset / Trial / NCT05465902
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral Vector COVID-19 vaccines (one or two doses) and have not been infected with COVID-19. All subjects will be evaluated for safety and immunogenicity after a single dose booster immunization with Recombinant COVID-19 variant Vaccine (Sf9 Cell) or inactivated COVID-19 vaccine (Vero cell) or mRNA vaccine or Viral Vector vaccine.
Timeline
- Start
- 2023-07-07
- Primary completion
- 2024-11-30
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | — | Intramuscular |
| Subject | Recombinant COVID-19 Variant Vaccine (Sf9 Cell) | Vaccine | — | Intramuscular |
| Comparator | Viral Vector COVID-19 vaccine (AstraZeneca) | Unknown | — | Intramuscular |
| Comparator | mRNA COVID-19 vaccine (Moderna) | Messenger RNA (mRNA) | — | Intramuscular |